<DOC>
	<DOCNO>NCT01136382</DOCNO>
	<brief_summary>This purpose study investigate budesonide pMDI 160 �g twice day 6 week effective safe treat asthmatic child age 6 &lt; 12 year</brief_summary>
	<brief_title>A 6-week Study Asthmatic Children Aged 6 &lt; 12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo</brief_title>
	<detailed_description>Phase 2 , double-blind , randomize , parallel-group , placebo-controlled , multicenter study , compare budesonide pMDI 160 �g bid placebo : 6-week efficacy safety study child age 6 &lt; 12 year asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Has document clinical diagnosis asthma least 6 month prior Visit 2 require daily inhale corticosteroid low dose range OR LTRA monotherapy least 30 day prior Visit 2 . Has morning clinic prebronchodilator FEV1 measure least 6 hour last dose inhale short act beta agonist great equal 70 % less equal 95 % predict normal Demonstrated reversibility FEV1 ≥12 % pre short act beta agonist level within 15 30 minute administration standard dose short act beta agonist OR document reversibility ≥ 12 % within 12 month prior Visit 2 . Has hospitalize least required emergency treatment ( see emergency room urgent care visit ) asthmarelated condition 6 month prior Visit 2 Has require treatment systemic corticosteroid ( eg , oral , parenteral , rectal ) reason within 12 week prior Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>asthma , child , budesonide pMDI</keyword>
</DOC>